Technical Analysis for STML - Stemline Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 10.53 -0.57% -0.06
STML closed down 0.57 percent on Tuesday, November 20, 2018, on 1.5 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical STML trend table...

Date Alert Name Type % Chg
Nov 20 New 52 Week Closing Low Bearish 0.00%
Nov 20 Doji - Bullish? Reversal 0.00%
Nov 20 New 52 Week Low Weakness 0.00%
Nov 20 Wide Bands Range Expansion 0.00%
Nov 20 Oversold Stochastic Weakness 0.00%
Nov 19 New 52 Week Closing Low Bearish -0.57%
Nov 19 Lower Bollinger Band Walk Weakness -0.57%
Nov 19 New 52 Week Low Weakness -0.57%
Nov 19 Wide Bands Range Expansion -0.57%
Nov 19 Lower Bollinger Band Touch Weakness -0.57%

Older signals for STML ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing proprietary therapeutics that target cancer stem cells (CSCs) and tumor bulk. It develops StemScreen platform technology consisting of StemScreen-1 and StemScreen-2 for the identification of novel CSC-directed compounds. The company is developing SL-401, a biologic-drug conjugate, which has completed Phase I/II clinical trial for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine that has completed two Phase I/II clinical trials for pediatric and adult high-grade gliomas. Its products under preclinical stage include SL-301, a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types; SL-101, a mAb-based compound that targets CD123; SL-201, a small molecule active against certain hematologic and solid tumor types; and SL-601, mAb-based compound that targets a cell surface marker on bladder CSCs. The company also in-licensed intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened, and Patched. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
Is STML a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 20.55
52 Week Low 10.37
Average Volume 210,514
200-Day Moving Average 16.4048
50-Day Moving Average 15.3903
20-Day Moving Average 13.689
10-Day Moving Average 12.206
Average True Range 0.802
ADX 42.05
+DI 5.5216
-DI 35.797
Chandelier Exit (Long, 3 ATRs ) 13.814
Chandelier Exit (Short, 3 ATRs ) 12.776
Upper Bollinger Band 17.334
Lower Bollinger Band 10.044
Percent B (%b) 0.07
BandWidth 53.254438
MACD Line -1.3316
MACD Signal Line -0.9721
MACD Histogram -0.3596
Fundamentals Value
Market Cap 246.98 Million
Num Shares 23.5 Million
EPS -2.47
Price-to-Earnings (P/E) Ratio -4.26
Price-to-Sales 202.21
Price-to-Book 3.03
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.48
Resistance 3 (R3) 11.53 11.26 11.32
Resistance 2 (R2) 11.26 11.02 11.24 11.26
Resistance 1 (R1) 10.90 10.87 10.77 10.85 11.21
Pivot Point 10.63 10.63 10.57 10.61 10.63
Support 1 (S1) 10.27 10.39 10.14 10.22 9.85
Support 2 (S2) 10.00 10.24 9.98 9.80
Support 3 (S3) 9.64 10.00 9.74
Support 4 (S4) 9.59